SunTrust Banks Reaffirms “Buy” Rating for Tetraphase Pharmaceuticals (TTPH)

Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “buy” rating reiterated by equities research analysts at SunTrust Banks in a report issued on Wednesday. They currently have a $10.00 target price on the biopharmaceutical company’s stock. SunTrust Banks’ price target would suggest a potential upside of 84.16% from the company’s current price.

TTPH has been the topic of several other research reports. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 12th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. B. Riley started coverage on shares of Tetraphase Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $11.00 price target on the stock. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $10.39.

Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down $0.03 during trading on Wednesday, hitting $5.43. 1,225,600 shares of the stock traded hands, compared to its average volume of 944,575. The company has a market capitalization of $281.71, a PE ratio of -1.90 and a beta of 2.29. Tetraphase Pharmaceuticals has a 52-week low of $2.10 and a 52-week high of $9.93.

In related news, Director L Patrick Gage bought 3,880 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The stock was bought at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares of the company’s stock, valued at $250,776. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $6.21, for a total transaction of $44,507.07. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the stock. Deutsche Bank AG grew its position in Tetraphase Pharmaceuticals by 168.6% in the fourth quarter. Deutsche Bank AG now owns 221,425 shares of the biopharmaceutical company’s stock worth $1,394,000 after acquiring an additional 138,996 shares in the last quarter. Renaissance Technologies LLC grew its position in Tetraphase Pharmaceuticals by 77.6% in the fourth quarter. Renaissance Technologies LLC now owns 592,493 shares of the biopharmaceutical company’s stock worth $3,733,000 after acquiring an additional 258,908 shares in the last quarter. AXA grew its position in Tetraphase Pharmaceuticals by 7.1% in the fourth quarter. AXA now owns 216,337 shares of the biopharmaceutical company’s stock worth $1,363,000 after acquiring an additional 14,400 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in Tetraphase Pharmaceuticals in the fourth quarter worth $376,000. Finally, BlackRock Inc. grew its position in Tetraphase Pharmaceuticals by 21.2% in the fourth quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock worth $25,479,000 after acquiring an additional 707,296 shares in the last quarter. Institutional investors own 58.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: “SunTrust Banks Reaffirms “Buy” Rating for Tetraphase Pharmaceuticals (TTPH)” was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.themarketsdaily.com/2018/02/14/suntrust-banks-reaffirms-buy-rating-for-tetraphase-pharmaceuticals-ttph.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply